28 mayo 2015
The monoclonal antibody nivolumab has shown promise as a therapeutic agent, particularly by improving the survival rates of melanoma patients. Medical researchers have presented data from a retrospective analysis of the safety of nivolumab in 4 ongoing phase I-III studies in melanoma patients.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/1ka5axfJV2g/150528153517.htm
